Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease
NCT ID: NCT01178047
Last Updated: 2012-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
1 participants
INTERVENTIONAL
2011-09-30
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Rasagiline is a potent, highly selective, irreversible, second-generation, monoamine oxidase type-B (MAO-B) inhibitor with a 24h dopaminergic effect.
It is well known that dopaminergic treatment closely interacts with SWD. This study aims to assess the effect of Rasagiline on SWD in PD patients. In this randomized, double-blind, placebo controlled study in clinical phase IV, 60 subjects will be treated with rasagiline 1mg po once daily or placebo over 8 weeks. The study is planned to be conducted in 6-9 Swiss centers. Questionaires will be used to assess SWDs: sleep disturbances (Parkinson's Disease Sleep Scale, PDSS), daytime sleepiness (Epworth Sleepiness Scale, ESS), fatigue (Fatigue Severity Scale, FSS), apathy (Apathy Evaluation Scale Self, AES-S), disability (Sheehan scale) and QoL in PD patients.
* Trial with medicinal product
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rasagiline
Rasagiline
Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
Placebo
Rasagiline
Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rasagiline
Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Hoehn and Yahr up to stage 3 in the off-state
3. Age = 40 years
4. On the basis of a physical examination and medical history, the patient is in the investigator's opinion otherwise healthy
5. Parkinson's Disease Sleep Scale (PDSS) score = 90.
6. Patients with stable dosage of hypnotics / sedative /neuropsychiatric treatment including antiParkinsonian treatment in the last 4 weeks before screening evaluation and with no change foreseen during the study period. Dose adjustments can be made, but no change or discontinuation of drugs.
7. Subjects must understand questionnaires in German, French or Italian
8. Provided signed informed consent
9. Females of childbearing potential must agree to utilize highly effective contraceptive methods of birth control.
10. Females of child bearing potential must have a negative pregnancy test.
Exclusion Criteria
2. Patients with cognitive deficit (MMSE \< 26)
3. Patients who have undergone surgery for the treatment of PD
4. Patients with non-response to adequate antiParkinsonian treatment
5. History of moderate to severe hepatic insufficiency.
6. Clinically relevant or unstable vascular disease
7. History of drug or alcohol abuse (within the past 10 years)
8. Patients with a history of psychotic disorders
9. Patients with treatment resistant/recurrent major depression (HADS =19)
10. Patients with unstable dosage of antiParkinsonian or neuropsychiatric treatment in the last 4 weeks before screening evaluation.
11. Concomitant use of fluoxetine, fluvoxamine, pethidine or monoamine oxidase inhibitors (MAOI) during the course of the study and within 3 months prior to screening evaluation. Patient may be rescreened 3 months after discontinuation of the above mentioned drugs.
12. Concomitant use of dextromethorphan, ephedrine or pseudoephedrine during the course of the study
13. Women who are pregnant or lactating
14. Participation in another study during or up to 30 days prior to participation in this study
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lundbeck A/S
INDUSTRY
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Baumann, Assoc Prof, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Zurich, Neurology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital, Neurology
Zurich, Canton of Zurich, Switzerland
Neurocentro, Lugano
Lugano, Lugano, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ras-PDS-1
Identifier Type: -
Identifier Source: org_study_id